Protagonist Therapeutics (PTGX) Preferred Stock Liabilities (2015 - 2016)
Protagonist Therapeutics (PTGX) posted Preferred Stock Liabilities of $66.6 million for Q2 2016, up 80.05% sequentially from $37.0 million in Q4 2015.
Protagonist Therapeutics (PTGX) Preferred Stock Liabilities (2015 - 2016) Analysis & Trends
Protagonist Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $66.6 million in Q2 2016.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $66.6 million in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $66.6 million (changed N/A YoY) and the FY2015 annual result came in at $37.0 million, up 79.8% from the prior year.
- Preferred Stock Liabilities grew to $66.6 million in Q2 2016 per PTGX's latest filing, from $37.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $66.6 million in Q2 2016 and troughed at $37.0 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 66.61 Mn |
| Dec 31, 2015 | 37.00 Mn |